Evidence map›Paper›PMID 29208669›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion.

Alessandra M Richardson, Lauren S Havel, Allyson E Koyen, Jessica M Konen, John Shupe, W G Wiles, W David Martin, Hans E Grossniklaus, Gabriel Sica, Melissa Gilbert-Ross and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

136 citing papers in PubMed, 1 synthesis or guideline pooled it, 228 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Collective migration modes in development, tissue repair and cancer.Nature reviews. Molecular cell biology · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

76 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Alessandra M RichardsonCancer Biology Graduate Program, Emory University, Atlanta, Georgia.
Lauren S HavelDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia.
Allyson E KoyenCancer Biology Graduate Program, Emory University, Atlanta, Georgia.
Jessica M KonenCancer Biology Graduate Program, Emory University, Atlanta, Georgia.
John ShupeDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia.
W G WilesWinship Cancer Institute of Emory University, Atlanta, Georgia.
W David MartinWinship Cancer Institute of Emory University, Atlanta, Georgia.
Hans E GrossniklausWinship Cancer Institute of Emory University, Atlanta, Georgia.
Gabriel SicaWinship Cancer Institute of Emory University, Atlanta, Georgia.
Melissa Gilbert-RossDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia. aimarcu@emory.edu mmgilbe@emory.edu.
Adam I MarcusDepartment of Hematology and Medical Oncology, Emory University, Atlanta, Georgia. aimarcu@emory.edu mmgilbe@emory.edu.
Emory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Systems analysis of phenotypic switch in control of cancer invasionU54CA209992 · NCI · YALE UNIVERSITY · PI LEVCHENKO, ANDRE · 2016 to 2021
$10.1M
Developing a pharmacologic approach to treat LKB1 mutant NSCLC patientsR01CA194027 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.5M
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer S1R01CA201340 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.0M
Control of lung cancer invasion and metastasis by vimentinR01CA142858 · NCI · EMORY UNIVERSITY · PI MARCUS, ADAM I. · 2011 to 2015
$1.6M
Deciphering vimentin phosphorylation in cancer cell invasion and metastasisF31CA189772 · NCI · EMORY UNIVERSITY · PI RICHARDSON, ALESSANDRA · 2014 to 2017
$130k
NCI NIH HHS F31 CA189772NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA142858NCI NIH HHS R01 CA194027NCI NIH HHS R01 CA201340NCI NIH HHS U54 CA209992
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungAMP-Activated Protein Kinase KinasesAnimalsBiomarkers, TumorCancer-Associated FibroblastsCell CommunicationCell Line, TumorDisease Models, AnimalEpithelial-Mesenchymal TransitionGene ExpressionHumansImmunohistochemistryMice, KnockoutNeoplasm MetastasisProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)AMP-Activated Protein Kinase KinasesBiomarkers, TumorKRAS protein, humanProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STK11 protein, humanVimentin

Identifiers

PMID29208669
PMCPMC5771825
OpenAlexW2772121941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.